Relationships Between Köhne Category/Baseline Tumor Load and Early Tumor Shrinkage, Depth of Response, and Outcomes in Metastatic Colorectal Cancer.
No Thumbnail Available
Identifiers
Date
2021-05-25
Authors
Sartore-Bianchi, Andrea
García-Alfonso, Pilar
Geissler, Michael
Köhne, Claus-Henning
Peeters, Marc
Price, Timothy
Valladares-Ayerbes, Manuel
Zhang, Ying
Burdon, Peter
Taieb, Julien
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
In metastatic colorectal cancer (mCRC), there are limited data on associations between early tumor shrinkage (ETS), depth of response (DpR), and patient characteristics. Data from patients with RAS wild-type mCRC who had participated in the PRIME (NCT00364013) and PEAK (NCT00819780) studies were analyzed retrospectively. ETS and DpR were assessed by baseline Köhne category/BRAF status (PRIME) and baseline tumor load (pooled PRIME and PEAK). Analysis populations included 436 to 665 patients. Patients' chances of achieving ETS of 30% or greater were 63.8%, 50.4%, and 41.9% in the low-, medium-, and high-risk Köhne categories, and 21.7% in those with BRAF mutations. Corresponding percentages for the highest DpR classification (71%-100%) were 47.7% (low risk), 23.6% (medium risk), 10.0% (high risk), and 4.2% (BRAF mutant). No clear relationship was observed between baseline tumor load and ETS or DpR. An ETS of 30% or greater and higher DpR values were associated with statistically significant prolongation of median progression-free survival and overall survival. Patients with mCRC categorized at baseline by the Köhne criteria as high risk or with BRAF mutations have lower chances of achieving an ETS of 30% or greater or a high DpR. Baseline tumor load was not predictive of ETS or DpR. Favorable ETS or DpR is associated with improved progression-free and overall survival.
Description
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols
Colorectal Neoplasms
Humans
Rectal Neoplasms
Retrospective Studies
Tumor Burden
Colorectal Neoplasms
Humans
Rectal Neoplasms
Retrospective Studies
Tumor Burden
DeCS Terms
CIE Terms
Keywords
OS, PFS, Panitumumab, Risk, Volume, mCRC